NIKKEI 225
38,236.07 -37.98 (-0.10%) HANG SENG
18,207.13 +444.10 (+2.50%) CRUDE OIL
79.00 0.00 (0.00%) GOLD FUTURES
2,311.50 +0.50 (+0.02%) DOW
38,225.66 +322.37 (+0.85%) Bitcoin GBP
46,962.40 +1,136.81 (+2.48%)
MEDIROM Healthcare Technologies Inc. (MRM)
| Previous close | 5.42 |
| Open | 5.20 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 5.20 - 5.20 |
| 52-week range | 3.50 - 7.40 |
| Volume | |
| Avg. volume | 2,580 |
| Market cap | 26.756M |
| Beta (5Y monthly) | 0.02 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.05 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireMEDIROM Healthcare Technologies Inc. Announces March 2024 Key Performance Indicators (KPIs)
Total Customers Served: 77,854 – Sales Per Customer: JPY 7,190 – Customer Repeat Ratio: 77.9%TOKYO, April 25, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a holistic healthcare company based in Japan (the “Company”), today announced its major Key Performance Indicators, or KPIs, updated for the month of March 2024. Data is provided for all salons for which comparative financial and customer data is available and excludes certain salons where such information is
- GlobeNewswire
Announcement Execution of Memorandum of Understanding for Share Acquisition (Subsidiarization)
NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (“we”, “our” or “us”) hereby announces that we resolved, at a meeting of our Board of Directors held on March 29, 2024, to enter into a Memorandum of Understanding (the “MOU”) for the purpose of acquiring all of the shares of stock of Japan Gene Medicine Corporation (the “Target Company”) and making it our subsidiary, and commencing the processes and negotiations necessary to enter into the definitive agreement for
Simply Wall St.MEDIROM Healthcare Technologies First Half 2023 Earnings: JP¥72.72 loss per share (vs JP¥37.18 loss in 1H 2022)
MEDIROM Healthcare Technologies ( NASDAQ:MRM ) First Half 2023 Results Key Financial Results Revenue: JP¥3.24b (up 3.0...
